Payment overview · 2025
General Payments
$1,113.69
37 reported records · 13 companies
Healthcare provider profile · identity verified
Tracy Jansen, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PASADENA, MD · NPI 1922031210
Verified facts
What the public records show
CMS Open Payments records show Tracy Jansen, M.D. received $1,113.69 in general payments during 2025 across 37 reported records.
Dexcom, Inc. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $423.17 | 38.0% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $172.62 | 15.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $105.05 | 9.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.97 | 6.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $65.29 | 5.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.52 | 5.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.25 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.35 | 4.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.17 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.87 | 2.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.19 | 2.0% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $14.66 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.58 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,113.69 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $323.17 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $172.62 | 5 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.97 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $71.77 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $65.29 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.33 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.25 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.35 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.35 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.90 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $36.17 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 69 |
| Lisinopril | Lisinopril | 233 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 68 |
| Losartan Potassium | Losartan Potassium | 197 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 49 |
| Simvastatin | Simvastatin | 120 | 38 |
| Gabapentin | Gabapentin | 119 | 36 |
| Omeprazole | Omeprazole | 101 | 32 |
| Alprazolam | Alprazolam | 90 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 24 |
| Meloxicam | Meloxicam | 84 | 31 |
| Tramadol Hcl | Tramadol Hcl | 78 | 24 |
| Atenolol | Atenolol | 76 | 19 |
| Metformin Hcl | Metformin Hcl | 76 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 21 |
| Furosemide | Furosemide | 68 | 28 |
| Synthroid | Levothyroxine Sodium | 66 | 19 |
| Allopurinol | Allopurinol | 63 | 18 |
| Famotidine | Famotidine | 63 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 23 |
| Valsartan | Valsartan | 60 | 18 |
| Jardiance | Empagliflozin | 58 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 18 |
| Metformin Hcl Er | Metformin Hcl | 50 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 16 |
| Trazodone Hcl | Trazodone Hcl | 48 | 18 |
| Carvedilol | Carvedilol | 46 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 36 |
| Ozempic | Semaglutide | 45 | 15 |
| Sertraline Hcl | Sertraline Hcl | 43 | 15 |
| Glipizide Er | Glipizide | 42 | 14 |
| Potassium Chloride | Potassium Chloride | 42 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 15 |
| Bupropion Xl | Bupropion Hcl | 38 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 16 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Eliquis | Apixaban | 34 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 14 |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 19 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Diazepam | Diazepam | 18 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,113.69 · 37 records | Dexcom, Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ELIQUIS, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, PREVNAR 20, REPATHA, VRAYLAR, VYEPTI, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error